Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Department of Health, Generalitat de Catalunya | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Introduction: Following pulmonary transplantation (PT), peripheral and respiratory muscle weakness, and associated global malfunction are some of the limiting factors in rapid recovery. Effective early implantation pulmonary rehabilitation programs are currently lacking.
Objectives: To introduce an early rehabilitation program in the ICU after PT to see if there is an improvement in functionality, an increase in strength and muscle mass, an improvement in the strength of the respiratory muscles and a shorter hospitalization time in the ICU and in the ward.
Methodology: A single-blind randomized clinical trial will be performed to divide patients with PT into one experimental group and another control group. Prior to the PT, those patients between the ages of 18 and 70 will be recruited, to be admitted to the ICU of Vall Hebron University Hospital, and who have been prescribed pulmonary rehabilitation with onset in the first 15 days after the surgery. The control group receives regular treatment in the ICU, which includes muscle strengthening exercises, passive/assisted or active mobilizations, and respiratory physiotherapy with breathing muscle strengthening in a medium load. The experimental group receives a new early rehabilitation program based on a patient's in-bed cycling that allows controlled and adapted training to the patient's situation, along with coordinated exercise with neuromuscular electrostimulation and respiratory physiotherapy with breathing muscle strengthening in a high load. Improvement will be observed through functional scales (6MWT), muscle dynamometry, manual muscle test (MRC-SumScore), bioimpedanciometry, inspiratory and maximal expiratory pressures, spirometry, frailty and sarcopenia tests and a long-term Cardiopulmonary Exercise Testing.
Expected Outcomes: Patients who perform the experimental group are expected to have an early discharge from the ICU and a reduction of the total hospital admission. Is also expected that the experimental group will improve the functional capacity and muscular strength, and they will have a lower risk of fragility in long term. It is also expected that the patients in the experimental group will soon be able to normalize their oxygen consumption a year after lung transplantation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Active Comparator | The control group receives regular treatment in the ICU, which includes muscle strengthening exercises, passive/assisted or active mobilizations, and respiratory physiotherapy with breathing muscle strengthening in a medium load (initially at 40% load from results in MIP). |
|
| Group 2 | Experimental | The experimental group receives a new early rehabilitation program based on a patient's in-bed cycling that allows controlled and adapted training to the patient's situation, along with coordinated exercise with neuromuscular electrostimulation and respiratory physiotherapy with breathing muscle strengthening in a high load (initially at 60% load from results in MIP). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Usual care treatment | Other | All evaluations are the same in both groups: Baseline evaluation ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery). Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value. 2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge. Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training. 4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery) |
| Measure | Description | Time Frame |
|---|---|---|
| Exercise Capacity | Measured with 6MWT It will be measured in different moments: Baseline Hospital discharge After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
| Muscle strength | Measured with dynamometer It will be measured in different moments Baseline When patient awake in ICU (RASS -1/0) Hospital discharge After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
| Muscle mass | Measured with bioimpedanciometry It will be measured in different moments: Baseline Hospital discharge After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
| Respiratory muscle strength | Measured with MIP and MEP It will be measured in different moments Baseline When patient awake in ICU (RASS -1/0) Hospital discharge After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
| Cough strength | Measured with Peak Cough Flow It will be measured in different moments Baseline When patient awake in ICU (RASS -1/0) Hospital discharge After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Frailty | Measured with the short physical performance battery test (SPPB test) SPPB (maximum 12 points)
It will be measured in different moments: Baseline Hospital discharge After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bernat Planas Pascual, PT, MSc | Hospital Universitari Vall d'Hebron Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitari Vall d'Hebron Research Institute | Barcelona | 08035 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21940789 | Background | du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9. doi: 10.1164/rccm.201105-0840OC. Epub 2011 Sep 22. | |
| 21536362 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| New Treatment Protocol-MotoMED® | Other | Baseline evaluation ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery). Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value. 2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge. Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training. 4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery) |
|
|
| Muscle balance | Measured with the Medical Research Council sum score test It will be measured in different moments Baseline When patient awake in ICU (RASS -1/0) Hospital discharge After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
| Pulmonary Capacity | Measured with a spirometer We will interpret the data obtained from forced spirometry to evaluate how our patient's pulmonary functions is developing after the surgery. Data collection: FEV1/FVC: It represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC).The result of this ratio is expressed as FEV1%. The normal value for the FEV1/FVC ratio is 70% (and 65% in persons older than age 65). It will be measured in different moments Baseline 1 year after the discharge | Through study completion, an average of 1 year |
| Oxygen consumption | Measured with the Cardiopulmonary effort test It will be measured in different moments After 1 month of discharge After 4 month of discharge 1 year after the discharge | Through study completion, an average of 1 year |
| Background |
| Roman A, Ussetti P, Sole A, Zurbano F, Borro JM, Vaquero JM, de Pablo A, Morales P, Blanco M, Bravo C, Cifrian J, de la Torre M, Gamez P, Laporta R, Monforte V, Mons R, Salvatierra A, Santos F, Sole J, Varela A; Sociedad Espanola de Neumologia y Cirugia Toracica. Guidelines for the selection of lung transplantation candidates. Arch Bronconeumol. 2011 Jun;47(6):303-9. doi: 10.1016/j.arbres.2011.03.007. Epub 2011 May 4. English, Spanish. |
| 22939738 | Background | Coll E, Santos F, Ussetti P, Canela M, Borro JM, De La Torre M, Varela A, Zurbano F, Mons R, Morales P, Pastor J, Salvatierra A, de Pablo A, Gamez P, Moreno A, Sole J, Roman A. The Spanish Lung Transplant Registry: first report of results (2006-2010). Arch Bronconeumol. 2013 Feb;49(2):70-8. doi: 10.1016/j.arbres.2012.06.001. Epub 2012 Aug 28. English, Spanish. |
| 25085497 | Background | Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15. doi: 10.1016/j.healun.2014.06.014. Epub 2014 Jun 26. |
| 30174910 | Background | Weill D. Lung transplantation: indications and contraindications. J Thorac Dis. 2018 Jul;10(7):4574-4587. doi: 10.21037/jtd.2018.06.141. |
| 22300103 | Background | Shigemura N, Bhama J, Gries CJ, Kawamura T, Crespo M, Johnson B, Zaldonis D, Pilewski J, Toyoda Y, Bermudez C. Lung transplantation in patients with prior cardiothoracic surgical procedures. Am J Transplant. 2012 May;12(5):1249-55. doi: 10.1111/j.1600-6143.2011.03946.x. Epub 2012 Feb 2. |
| 18724219 | Background | Reynaud-Gaubert M, Mornex JF, Mal H, Treilhaud M, Dromer C, Quetant S, Leroy-Ladurie F, Guillemain R, Philit F, Dauriat G, Grenet D, Stern M. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation. 2008 Aug 27;86(4):515-20. doi: 10.1097/TP.0b013e31817c15df. |
| 7598576 | Background | Detterbeck FC, Egan TM, Mill MR. Lung transplantation after previous thoracic surgical procedures. Ann Thorac Surg. 1995 Jul;60(1):139-43. |
| 15982615 | Background | Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant. 2005 Jul;24(7):865-9. doi: 10.1016/j.healun.2004.05.024. |
| 10673212 | Background | American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64. doi: 10.1164/ajrccm.161.2.ats3-00. No abstract available. |
| 21471066 | Background | Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL. |
| 21616999 | Background | du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66. doi: 10.1164/rccm.201011-1790OC. |
| 15994263 | Background | de Gracia J, Mata F, Alvarez A, Casals T, Gatner S, Vendrell M, de la Rosa D, Guarner L, Hermosilla E. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax. 2005 Jul;60(7):558-63. doi: 10.1136/thx.2004.031153. |
| 12873544 | Background | De Soyza A, Archer L, Wardle J, Parry G, Dark JH, Gould K, Corris PA. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant. 2003 Jul;22(7):764-9. doi: 10.1016/s1053-2498(02)00641-1. |
| 15302726 | Background | Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004 Aug;126(2):412-9. doi: 10.1378/chest.126.2.412. |
| Background | A.R.Damasio. The New England Journal of Medicine Downloaded from nejm.org at the Bodleian Libraries of the University of Oxford on February 16, 2014. For personal use only. No other uses without permission. Copyright © 1992 Massachusetts Medical Society. All rights re. N Engl J Med. 1992;327(26):1832-5. |
| 12406843 | Background | Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 1):1550-5. doi: 10.1164/rccm.200202-087OC. Epub 2002 Aug 15. |
| 15695493 | Background | Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005 May 1;171(9):1053-9. doi: 10.1164/rccm.200407-900OC. Epub 2005 Feb 1. |
| 15502116 | Background | Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel PR, Dhainaut JF, Dusser D. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005 Jan 15;171(2):158-64. doi: 10.1164/rccm.200405-667OC. Epub 2004 Oct 22. |
| 30955510 | Background | Kim D, George MP. Pulmonary Hypertension. Med Clin North Am. 2019 May;103(3):413-423. doi: 10.1016/j.mcna.2018.12.002. |
| 24355641 | Background | Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032. |
| 19734361 | Background | Handoko ML, Lamberts RR, Redout EM, de Man FS, Boer C, Simonides WS, Paulus WJ, Westerhof N, Allaart CP, Vonk-Noordegraaf A. Right ventricular pacing improves right heart function in experimental pulmonary arterial hypertension: a study in the isolated heart. Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1752-9. doi: 10.1152/ajpheart.00555.2009. Epub 2009 Sep 4. |